Prognostic Markers in Histologic and Cytologic Specimens of Breast Cancer

Analytical and Quantitative Cytology and Histology

Volumn 25, Issue 5, 2003, Pages 297-302

  Klorin, Geula ^a   Keren, Ruth ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Aspiration biopsy; Breast cancer; Prognostic markers

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; C ERBB 2 GENE; CONTROLLED STUDY; CYTODIAGNOSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMEAR; TISSUE SECTION;

BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CYTODIAGNOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0142040213     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Costa MJ, Tadros T, Hilton G, Birdsong G: Breast fine needle aspiration cytology: Utility as a screening tool for clinically palpable lesions. Acta Cytol 1993;37:461-471
2. Meunier M, Clough K: Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions. Eur J Radiol 2002;42:10-16
3. Masood S: Estrogen and progesterone receptors in cytology: A comprehensive review. Diagn Cytopathol 1992;8:475-491
4. Masood S: Prognostic and diagnostic implication of estrogen and progesterone receptor assays in cytology. Diagn Cytopathol 1994;10:263-267
5. Corkill ME, Katz R: Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994;11:250-254
6. Harvey JN, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481
7. Allred DC, Harvey JN, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168
8. Osborne CK, Clark GM, Ravdin PM: Adjuvant systemic therapy of primary breast cancer. In Diseases of the Breast. Edited by JR Harris, ME Lippman, M Morrow, S Hellman. Philadelphia, Lippincott-Raven, 1996 pp 548-578
9. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996;74:1445-1451
10. Pertschuk LP, Feldman JG, Yong-Doo K, Braithwaite L, Schneider F, Braverman AS, Axiotis C: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer response more accurately than H222sp in frozen sections or cytosol-based ligand-binding assays. Cancer 1996;77:2514-2519
11. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spagnolli P, Manfrin E, Bonetti A, Nortilli R, Tomezzoli A, Pollini GP, Modena S, Cetto GL: Prognostic significance of estrogen receptors in 405 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997;45:241-249
12. Barnes DM, Millis RR, Beex LV, Thorpe SM, Leake RE: Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer 1998;34:1677-1682
13. Clark GM: Prognostic and predictive factors. In Diseases of the Breast. Edited by JR Harris, ME Lippman, M Morrow, S Hellman. Philadelphia, Lippincott-Raven, 1996, pp 461-485
14. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers: A review. Gene 1995;159:19-27
15. Pertschuk LP, Yong-Doo K, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assay in breast cancer with monoclonal antibodies: Histopathologic, demographic, and biochemical correlation and relationship to endocrine response and survival. Cancer 1990;66:1663-1670
16. Battifora H, Mehta P, Ahn CH, Esteban JM: Estrogen receptor immunohistochemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1993;1:39-45
17. Zoppi JA, Rotundo AV, Sundblad AS: Correlation of immunocytochemical and immunohistochemical determination of estrogen and progesterone receptors in breast cancer. Acta Cytol 2002;46:337-340
18. Tiniakos DG, Robinson KB, Greenwood H, Cullen P, Cook AI, Horne CH, Angus B: C-erb B-2 and p53 expression in breast cancer fine needle aspirates. Cytopathology 1996;7:178-186
19. Corkill ME, Katz R: Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994;11:250-254
20. Troncone G, Panico L, Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, Pettinato G, Palombini L: C-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 1996;14:135-139
21. Klorin G, Keren R: Prognostic evaluation of breast cancer in cytologic specimens. Analyt Quant Cytol Histol 2002;24:49-53
22. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-942
23. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-3063
24. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M: Pre-operative chemotherapy induces apoptosis in early breast cancer. Lancet 1997;349:849
25. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-2152
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
27. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
28. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989;49:7147-7152
29. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW: ErbB-2 amplification in breast cancer analysed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992;89:5321-5325
30. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C: The HER-2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-1032
31. Nizzoli R, Bozzetti C, Savoldi L, Manotti L, Naldi N, Camisa R, Soresi AP, Guazzi A, Cocconi G: Immunocytochemical assay of estrogen and progesterone receptors in fine needle aspirations from breast cancer patients. Acta Cytol 1994;38:933-938
32. Suthipintawong C, Leong AS-Y, Vinyuvat S: Immunostaining of cell preparations: A comparative evaluation of common fixatives and protocols. Diagn Cytopathol 1996;15:167-174
33. Suthipintawong C, Leong AS-Y, Chan KW, Vinyuvat S. Immunostaining of estrogen receptor, progesterone receptor, MIB1antigen, and c-erbB-2 oncoprotein in cytologic specimens: A simplified method with formalin fixation. Diagn Cytopathol 1997;17:127-133